Cannabinoid Pathways Show Promise as New Treatment Targets for Kidney Disease

Approximately 850 million people worldwide suffer from chronic kidney disease (CKD), representing 9.1% of the global population, with cases steadily rising over the past two decades. Current standard treatments like RAAS inhibitors and angiotensin receptor blockers help manage the condition but vary in effectiveness between patients and cannot halt disease progression. Researchers are now investigating cannabinoid pathways as potential new therapeutic targets to address this critical gap in kidney disease treatment. This research offers hope for developing more effective interventions that could stop rather than merely slow CKD progression. For Puerto Rico's population, where kidney disease prevalence is a significant health concern, these findings could lead to innovative treatment options.